Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) reported that the Committee for Orphan Medicinal Products at the European Medicines Agency adopted a positive opinion recommending orphan drug designation for imsidolimab, a high-affinity humanized IgG4 monoclonal antibody, for treating generalized pustular psoriasis (GPP).

According to Vanda, this is the first time the EMA has provided orphan drug designation recognition for a GPP treatment in the EU. Orphan status in Europe offers protocol assistance, reduced regulatory fees and market exclusivity after approval. The opinion follows similar regulatory recognitions in the US and Japan, and Vanda’s imsidolimab BLA for GPP is under FDA review with a target action date of December 12, 2026.

Positive

• EMA positive opinion recommending orphan drug designation for imsidolimab in GPP
• First EMA orphan recognition for a GPP treatment in the EU, per Vanda
• Potential EU benefits: protocol assistance, reduced fees, market exclusivity
• Regulatory momentum with similar recognitions in US and Japan
• Imsidolimab BLA under FDA review with action date December 12, 2026

Negative

• None.

News Market Reaction – VNDA

-0.18%

12 alerts

-0.18% Session close to close

-3.5% Trough in 4 hr 32 min

$351.79M Market Cap

1.3x Rel. Volume

In the Jul 17 session, VNDA declined 0.18%, reflecting a mild negative market reaction. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Clinical-tag news for VNDA has averaged a modest -1.79% move, with direction usually matching the ne...

Analysis

Clinical-tag news for VNDA has averaged a modest -1.79% move, with direction usually matching the news tone. Against that backdrop, EMA orphan recognition for imsidolimab fits a positive regulatory trend, though an effective $200,000,000 S-3 shelf means capital-raising and dilution risk remain key watchpoints.

Key Figures

EU rarity threshold: fewer than 5 in 10,000 people FDA target action date: December 12, 2026

2 metrics

EU rarity threshold fewer than 5 in 10,000 people Criteria for EMA orphan drug designation

FDA target action date December 12, 2026 Imsidolimab BLA for generalized pustular psoriasis

Previous Clinical trial Reports

5 past events · Latest: May 27 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 27	Orphan designation Japan	Positive	+3.9%	Japan granted orphan drug designation to imsidolimab for GPP.
Apr 08	Phase 2 trial start	Positive	+0.6%	Initiation of Thetis Phase 2 trial of NEREUS for GLP-1–related vomiting.
Feb 25	BLA acceptance	Positive	+1.4%	FDA accepted imsidolimab BLA for GPP with a defined action date.
Jan 08	FDA setback	Negative	-14.1%	FDA said HETLIOZ sNDA for jet lag could not be approved as filed.
Nov 05	Conference participation	Neutral	-0.7%	Company highlighted upcoming presentation at a major healthcare conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

For clinical and regulatory milestones, VNDA’s share moves have generally tracked the news tone, though the clinical-tag average move of -1.79% reflects one materially negative FDA outcome.

Key Terms

orphan drug designation, biologics license application, monoclonal antibody, interleukin-36, +1 more

5 terms

orphan drug designation regulatory

"has adopted a positive opinion recommending orphan drug designation for imsidolimab"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

biologics license application regulatory

"the imsidolimab Biologics License Application (BLA) for GPP is currently under review"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

monoclonal antibody medical

"a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

interleukin-36 medical

"driven by dysregulation in the interleukin-36 (IL-36) signaling pathway"

Interleukin-36 is a group of immune signaling proteins that help control inflammation by turning immune responses up or down, like a thermostat for the body’s defense system. It matters to investors because drugs or tests that alter or measure these proteins can become treatments or diagnostics for inflammatory and autoimmune diseases, affecting a biotech or pharmaceutical company’s clinical prospects, regulatory outlook, and potential market value.

immunoglobulin G4 medical

"a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody"

Immunoglobulin G4 (IgG4) is one of the four subtypes of the IgG antibody class produced by the immune system; antibodies act like identification tags that recognize and bind specific targets such as pathogens or the body's own tissues. IgG4 matters to investors because its levels and behavior are used in medical tests, influence classification of certain autoimmune conditions, and are a focus for diagnostic tools and antibody therapies—developments in these areas can affect clinical trial results, regulatory decisions, and the commercial prospects of biotech and diagnostics companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).

This marks the first time the EMA has granted orphan drug designation recognition for a drug to treat GPP in the European Union (EU). GPP is a severe, chronic, and potentially life-threatening inflammatory skin disease, genetically and clinically distinct from plaque psoriasis, driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ It is characterized by widespread pustular eruptions, systemic inflammation, and serious complications that can lead to increased mortality.²³⁴

Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36 receptor antagonist commonly observed in patients with GPP.

The EMA's orphan drug designation is granted to medicines intended for the treatment of life-threatening or chronically debilitating rare conditions affecting fewer than 5 in 10,000 people in the EU. Benefits include protocol assistance, reduced regulatory fees, and market exclusivity provisions in the EU following approval.

"The EMA's positive opinion is a significant milestone that reinforces the highly encouraging clinical data supporting the imsidolimab program and formally recognizes GPP as an orphan disease in the EU for the first time," said Dr. Mihael H. Polymeropoulos, "This designation highlights the urgent unmet medical need in GPP and brings us one step closer to delivering a meaningful new therapy to patients in the EU."

This designation follows similar regulatory recognitions in the United States and Japan. Additionally, the imsidolimab Biologics License Application (BLA) for GPP is currently under review by the FDA with a target action date of December 12, 2026.

References

1. Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. NEJM Evidence 5, (2026).
2. Ministry of Health Labour and Welfare (MHLW), "Pustular psoriasis (generalized type) (Designated Intractable Disease 37)," Japan Intractable Diseases Information Center. Accessed: Mar. 10, 2026. [Online]. Available: https://www.nanbyou.or.jp/entry/168
3. H. Fujita, R. Iwasaki, S. Tsuboi, Y. Murashiuma, and M. Akiyama, "Regional differences in the prevalence of generalized pustular psoriasis in Japan," J. Dermatol., vol. 51, no. 3, pp. 380–390, Mar. 2024, doi: 10.1111/1346-8138.17089.
4. H. Miyachi et al., "Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan," J. Am. Acad. Dermatol., vol. 86, no. 6, pp. 1266–1274, Jun. 2022, doi: 10.1016/j.jaad.2021.06.008.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this press release, including but not limited to statements regarding the potential benefits associated with EMA approval of an orphan drug, the therapeutic potential of imsidolimab for patients with GPP in the EU, and the anticipated timing of the completion of the FDA's review of the imsidolimab BLA are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's ability to obtain approval of, and to successfully commercialize, imsidolimab in the EU for the treatment of patients with GPP, Vanda's ability to satisfy the conditions necessary to receive the benefits associated with EMA approval of an orphan drug, and the FDA's ability to complete its review of, and reach a decision with respect to, the imsidolimab BLA by December 12, 2026. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Follow us on X @vandapharma

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-ema-positive-opinion-for-orphan-drug-designation-of-imsidolimab-for-generalized-pustular-psoriasis--a-milestone-recognition-of-gpp-as-a-distinct-rare-disease-in-europe-302827934.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What did the EMA positive opinion on imsidolimab mean for Vanda (NASDAQ: VNDA) in July 2026?

The EMA committee issued a positive opinion recommending orphan drug designation for imsidolimab in generalized pustular psoriasis. According to Vanda, this recognizes GPP as an orphan disease in the EU and could grant regulatory support, reduced fees and post-approval market exclusivity if designation and approval follow.

What is imsidolimab and how could it help generalized pustular psoriasis (GPP) patients?

Imsidolimab is Vanda’s investigational humanized IgG4 monoclonal antibody targeting IL-36 receptor signaling. According to Vanda, it inhibits IL-36 receptor signaling to address deficiency of the endogenous IL-36 receptor antagonist often seen in GPP, a severe, chronic and potentially life-threatening inflammatory skin disease.

What benefits does EMA orphan drug designation offer for Vanda’s imsidolimab in the EU?

EMA orphan designation can provide protocol assistance, reduced regulatory fees and market exclusivity after approval. According to Vanda, these incentives would apply to imsidolimab in generalized pustular psoriasis if the positive opinion leads to formal orphan designation and subsequent marketing authorization in the European Union.

How does the EMA orphan opinion on imsidolimab relate to Vanda’s FDA BLA review (VNDA)?

The EMA opinion complements Vanda’s ongoing Biologics License Application review for imsidolimab in GPP by the FDA. According to Vanda, the FDA review has a target action date of December 12, 2026, highlighting parallel regulatory pathways in the United States and European Union.

Has imsidolimab received orphan or rare disease recognition outside Europe before this EMA opinion?

Yes. According to Vanda, the EMA positive opinion for orphan designation in GPP follows similar regulatory recognitions in the United States and Japan. This suggests imsidolimab’s rare disease positioning for generalized pustular psoriasis across multiple major markets, pending final designations and approvals.

Why is the EMA’s recognition of GPP as an orphan disease important for Vanda (VNDA)?

Recognition of GPP as an orphan disease in the EU supports development incentives and underscores unmet medical need. According to Vanda, this is the first such EMA orphan recognition for GPP, potentially strengthening imsidolimab’s strategic position and regulatory support if the designation is finalized.